Linked Life Data

21197741

Source:http://linkedlifedata.com/resource/pubmed/id/21197741

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2010-12-31
pubmed:abstractText
Since cancer biology is now better understood, molecular targets involved in tumorigenesis have been identified and specific "targeted therapy" has been designed. Antiangiogenic and anti-EGFR are the 2 targeted families of drugs introduced in the management of colorectal cancer. Bevacizumab, cetuximab and panitumumab are well tolerated and improve the pronostic of the patients in combination with conventional chemotherapy. Moreover, the mutation of KRAS gene has been recently identified as a predictive factor of resistance to anti-EGFR and allows a better selection of the patients. Formely based on 5FU, the management of advanced colorectal cancer is now involving a complex multidisciplinary strategy combining conventional chemotherapy, targeted agents, and surgery with curative intent whenever possible.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0035-2640
pubmed:author
pubmed:issnType
Print
pubmed:day
20
pubmed:volume
60
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1094-9
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
[Targeted therapies in colorectal cancer].
pubmed:affiliation
Service interhospitalier de cancérologie Bichat-Beaujon, Hôpital Beaujon, AP-HP, 92118 Clichy Cedex. marie-paule.sablin@bjn.aphp.fr
pubmed:publicationType
Journal Article, English Abstract